Q BioMed Inc. (OTCQB: QBIO) is a biomedical acceleration and development company. We are focused on licensing and acquiring undervalued and under-appreciated biomedical assets. QBIO is dedicated to providing these target assets, the strategic resources, developmental support, and expansion capital to ensure they meet their potential. The end result being value recognition and ultimately enabling them to provide products to patients in need.
The company has a growing pipeline of drugs and therapies to treat metastatic cancer bone pain, autism, liver cancer, glaucoma and complications linked to coronavirus (COVID-19)